Search tips
Search criteria

Results 1-25 (574406)

Clipboard (0)

Related Articles

1.  Clinical efficacy of Coleus forskohlii (Willd.) Briq. (Makandi) in hypertension of geriatric population 
Ayu  2011;32(1):59-65.
Hypertension is the most common psychosomatic disorder affecting 972 million people worldwide. The present clinical study deals with the effect of Makandi (Coleus forskohlii (Willd.) Briq.) Ghana vati and tablets of its powder in hypertension found in the geriatric age group (50-80 years). A total of 49 hypertensive patients fulfilling the diagnostic criteria were registered in two groups-Group I (Ghana vati) and Group II (Churna tablet). Out of 27 enrolled patients of group I, 21 patients completed the treatment. In Group II, out of 22 registered patients, a total of 20 patients completed the treatment. The effect of the therapy was assessed on the basis of changes in the systolic and diastolic blood pressures, in both sitting and supine positions; with Manasa Bhava Pariksha, Manasa Vibhrama Pariksha, symptomatology, geriatric signs and symptoms, and a brief psychiatric rating scale. Analysis of the results showed that the treatment in both the groups had been found to be good. It can be stated that Makandi, either in Ghana vati form or in churna tablet form, is an effective remedy for the treatment of hypertension. On analyzing the overall effect, 76.19% patients in Group I and 75.00% patients in Group II were mildly improved. Comparatively the overall treatment with group I was found to be better.
PMCID: PMC3215419  PMID: 22131759
Makandi; Coleus forskohlii; forskolin; Ghana vati; geriatric hypertension
2.  The role of psychic factors in pathogenesis of essential hypertension and its management by Shirodhara and Sarpagandha Vati 
Ayu  2010;31(4):436-441.
This clinical trial was conducted to evaluate the efficacy of Shirodhara and that of Sarpagandha Vati in essential hypertension. A total 47 patients were selected for study, out of which 40 patients (20 in each group) completed the course of treatment. Study subjects were randomly allotted into two groups, with one group being treated with Shirodhara and the other with Sarpagandha Vati. Specialized Ayurvedic rating scales like Manasa Pariksha Bhava as well as the Hamilton Anxiety Rating Scale were adopted to assess the effect of therapy. The effects of treatment on the chief complaints and the associated complaints were also evaluated. The results in the Shirodhara group were better than that in the Sarpagandha group. Although both Sarpagandha Vati and Shirodhara helped in reducing systolic and diastolic pressures, the effect of Shirodhara was more marked.
PMCID: PMC3202255  PMID: 22048535
Essential hypertension; Manasika Bhava; Psychic factors; Shirodhara; Sarpagandha Vati
3.  A comparative clinical study of Nyagrodhadi Ghanavati and Virechana Karma in the management of Madhumeha 
Ayu  2010;31(3):300-304.
Diabetes mellitus is a common chronic metabolic disorder prevalent all over the world. Virechana is the Shodhana procedure that is specific for the elimination of vitiated Pitta and Kapha doshas. Thus, in the present study, the Virechana process has been selected prior to the administration of Shamana drug. Nyagrodhadi churna is mentioned in Chakradatta, which is modified into Ghana form for easy administration and dose maintenance. The present study was conducted in two groups: Group A, Nyogrodhadi Ghana vati (Shamana therapy) and Group B, Virechana and Nyogrodhadi Ghana vati (combined therapy). A total of 42 patients were registered for the present study, in which 34 patients completed the and eight patients were dropouts. After evaluating the total effect of the therapies, it was observed that the Virechana and Nyagrodhadi Ghanavati (combined therapy) provided better relief in the patients of Madhumeha in comparison with Nyagrodhadi Ghanavati (Shamana therapy) alone.
PMCID: PMC3221062  PMID: 22131730
Madhumeha; Prameha; Diabetes mellitus; Shodhana; Virechana; Shamana
4.  The hypolipidemic activity of Ayurvedic medicine, Arogyavardhini vati in Triton WR-1339-induced hyperlipidemic rats: A comparison with fenofibrate 
Hyperlipidemia is a major risk factor of coronary heart disease. Currently available hypolipidemic drugs have been associated with number of side effects. Arogyavardhini vati, an Ayurvedic polyherbal formulation has been used for liver disorders. Therefore, present study was designed to evaluate the effect of Arogyavardhini vati in Triton WR-1339-induced hyperlipidemia in rats.
Anti-hyperlipidemic activity evaluation of Arogyavardhini vati against Triton WR-1339-induced hyperlipidemia in rats.
Materials and Methods:
Overnight fasted male Wistar rats (150-200 g) were randomly divided into normal control group [4% Dimethyl Sulfoxide (DMSO), i.p.], positive control group (Triton WR-1339 in 4% DMSO, 400 mg/kg, i.p.), standard drug treated (fenofibrate 65 mg/kg, p.o. for 7 days after inducing hyperlipidemia) and Arogyavardhini vati treated (50, 100, 200 mg/kg, p.o. for 7 days after inducing hyperlipidemia). Rat doses were calculated by extrapolating the equivalent human dose (therapeutic dose, sub-maximum, and maximum dose). Serum total cholesterol, triglyceride, low-density lipoprotein (LDL), high-density lipoprotein HDL, liver malondialdehyde (MDA), and glutathione (GSH) levels were estimated at end of experiments.
Arogyavardhini vati significantly decreased serum cholesterol, triglyceride, LDL, and C-reactive protein (CRP) and significantly increased serum HDL in a dose-dependent manner. Decreased MDA and increased GSH levels in liver were observed at all doses of Arogyavardhini vati (50, 100, 200 mg/kg) and fenofibrate-treated groups when compared with Triton-treated group. Atherogenic Index (AI) level was significantly decreased in fenofibrate and Arogyavardhini vati (200 mg/kg) treated rats when compared with normal control.
Arogyavardhini vati, a traditionally used Ayurvedic medicine may be a useful therapy for hypercholesterolemia through reducing oxidative stress (decreasing MDA and increasing GSH) and lipid levels.
PMCID: PMC3821191  PMID: 24250146
Arogyavardhini vati; atherogenic index; hypolipidemia; oxidative stress; Triton WR-1339
5.  OA01.05. Role of prabhakara vati and lekhana basti treatment in the management of coronary artery disease (Hridroga) 
Ancient Science of Life  2012;32(Suppl 1):S5.
The present study was conducted on 30 clinically diagnosed and confirmed patients of Coronary Artery Disease (C.A.D.). Patients having C.A.D. with specific conditions were not registered. The study was conducted with an objective of evaluating the role of Prabhakara Vati and Lekhana Basti in the management of C.A.D. on various scientific parameters.
30 patients were randomly divided into three groups. It was a randomised, comparative, open ended, pre and post design, clinical trial. Out of the three groups, 10 patients were administered Tab. Dilzem 30 mg TDS for one month, 10 patients of second group were administered Prabhakara Vati 500 mg (two tablets) bd for one month and 10 patients were administered Lekhana Basti (for 15 days) along with Prabhakara Vati 500 mg (two tablets) bd for one month.
During present trial it was observed that there was significant improvement in clinical manifestations of stable angina after the therapy with Prabhakara Vati and Lekhana Basti. The level of S. Cholesterol, L.D.L., V.L.D.L. and Serum Triglycerides decreased and the level of H.D.L. increased considerably after the therapy.
Prabhakara Vati and Lekhana Basti possesses potent antianginal and cardio protective activities and it can be used effectively in the management/to slow down the progress of pathogenesis of atherosclerosis leading to various Hridrogas (C.A.D.) specially stable angina.
PMCID: PMC3800929
6.  Prevalence, Awareness and Control of Hypertension in Uganda 
PLoS ONE  2013;8(4):e62236.
Prevention and control of hypertension are critical in reducing morbidity and mortality attributable to cardiovascular diseases. Awareness of hypertension is a pre-condition for control and prevention. This study estimated the proportion of adults who were hypertensive, were aware of their hypertension and those that achieved adequate control.
We conducted a community based cross sectional survey among people≥15 years in Buikwe and Mukono districts of Uganda. People had their blood pressure measured and were interviewed about their social-demographic characteristics. Hypertension was defined as systolic blood pressure ≥140 mmHg, or diastolic blood pressure ≥90 mmHg, or previous diagnosis of hypertension. Participants were classified as hypertensive aware if they reported that they had previously been informed by a health professional that they had hypertension. Control of hypertension among those aware was if systolic blood pressure was <140 mmHg and diastolic blood pressure was <90 mmHg.
The age standardized prevalence of hypertension was 27.2% (95% CI 25.9–28.5) similar among females (27.7%) and males (26.4%). Prevalence increased linearly with age, and age effect was more marked among females. Among the hypertensive participants, awareness was 28.2% (95% CI 25.4–31.0) higher among females (37.0%) compared to males (12.4%). Only 9.4% (95% CI 7.5–11.1) of all hypertensive participants were controlled. Control was higher among females (13.2%) compared to males (2.5%).
More than a quarter of the adult population had hypertension but awareness and control was very low. Measures are needed to enhance control, awareness and prevention of hypertension.
PMCID: PMC3629133  PMID: 23614041
7.  A comparative study of Rasona Rasnadi Ghanavati and Simhanada Guggulu on Amavata with special reference to Rheumatoid arthritis 
Ayu  2011;32(1):46-54.
The present study was aimed to assess the clinical effectiveness of Rasona Rasnadi Ghanavati and Simhanada Guggulu along with Rasona Rasnadi Lepa in Amavata, and to compare the effect of these two therapies in the treatment. Total 101 patients of Amavata were registered for the present study and were randomly divided into two groups. In group A- Rasona Rasnadi Ghanavati 2 Vati thrice/day was given for 3 months, while in group B- Simhanada Guggulu 2 Vati thrice a day for 3 months was adminstered. Along with this, Rasona Rasnadi Lepa was applied locally over affected joints twice daily in both groups. The effects of therapy in both groups were assessed by a specially prepared proforma. The results of the study showed that both the groups showed significant relief in symptoms; however, compared to Simhanada Guggulu, Rasona Rasnadi Ghanavati showed better result in the management of Amavata. Simhanada Guggulu or Rasona Rasnadi Ghanavati along with Rasona Rasnadi Lepa can be used as an effective ayurvedic intervention in the treatment for rheumatoid arthritis.
PMCID: PMC3215416  PMID: 22131757
Ama; Amavata; Rasona Rasnadi Ghanavati; Rheumatoid arthritis; Simhanada Guggulu; Vata
8.  PA01.06. Clinico comparative study of shodhan purvak shaman & shaman chikitsa in management of aamvata 
Ancient Science of Life  2012;32(Suppl 1):S55.
To compare the effect of shodhan purvak shaman & shaman chikitsa in management of aamvata.
Above study was planned in two parts conceptual & clinical For clinical part 40 patients having disease aamvata were randomly selected from opd & ipd & were divided in two groups. In shodhan purvak shaman group shodhan basti & shaman vati were given. Which was selected from classic text of ayurveda. In Shaman group only shaman yog vati was administered to the patients. Total duration of treatment in both groups was of 8 weeks.
Shodhan purvak shaman therapy has given complete remission in 6 patients, major improvement was found in 9 patients, 4 patients in minor improvement category and one in un improved category. In shaman therapy complete relief was found in 3 patients, major improvement in 12 patients, in minor improved category there were 5 patients no patient was found in unimproved category.
The results thus obtained were subjected to analytical statistical techniques to compare both modes of treatments. Critical assessment of total effect of therapies on individual patient reflects that shodhan therapy along with shaman vati was more effective in pacifying the symptoms of disease aamvata & bringing down the level of disease activity also as compared to shaman therapy alone. Mode of action of drug is discussed. No side effects were seen.
PMCID: PMC3800935
9.  A clinical study of Devadarvyadi-Vati on Grahani Dosha in children 
Ayu  2011;32(2):187-191.
Childhood period is considered as the period of rapid growth and development, as it is the crucial stage of establishing future. Gastro-intestinal disorders show high prevalence in pediatric practice. These conditions generally produce chronic illness. Grahanidosha is a disease related with Agnidushti. This condition is seen more in childhood period due to faulty dietary habit and changing lifestyle. The present paper deals with study on etiopathogenesis of Grahanidosha and evaluates the efficacy of Deavadarvyadi-Vati. The etiological factors and symptoms were observed carefully to make clear etiopathogenesis. Total 32 patients (3-12 years) were registered and randomly divided into two groups. In Group A Devadarvyadi-Vati (treated group) and in Group B Bhunimbadi-Vati (control group) given for 4 weeks with Koshna Jala. In Group A (Devadarvyadi-Vati), marked improvement was observed in 21.43% of the patients, moderate improvement was observed in 57.14% of patients and mild improvement was observed in 21.43% of patients.
PMCID: PMC3296338  PMID: 22408300
Bhunimbadivati; Devadarvyadivati; Grahani Dosha
10.  Rural and urban differences in blood pressure and pregnancy-induced hypertension among pregnant women in Ghana 
Globally, about 350.000 women die every year from pregnancy related causes and more than half of these deaths occur in sub-Saharan Africa (SSA). Approximately 12% of the maternal deaths are associated with hypertensive disorders in pregnancy such as pregnancy induced hypertension (PIH). However, very little is known about PIH and associated determinants in many SSA countries such as Ghana. We therefore sought to assess rural and urban differences in blood pressure (BP) and PIH among pregnant women in Ghana.
We conducted a cross-sectional study among 967 rural (677) and urban (290) pregnant women with a gestational age of more than 20 weeks. PIH was defined as a systolic blood pressure of ≥140 mmHg and/or diastolic blood pressure of ≥90 mmHg.
Women in urban Ghana had a higher mean systolic and diastolic BP than women in rural Ghana (105/66 mmHg versus 102/61 mmHg, p < 0.001 for both systolic and diastolic BP). The prevalence of PIH was also higher in urban Ghana (3.1%) than in rural Ghana (0.4%) (p = 0.014). The urban and rural difference in mean diastolic blood pressure persisted even after adjustments for the study characteristics in a linear regression model. In both rural and urban Ghana, BMI, heart rate and a family history of hypertension were independently associated with BP.
Our findings suggest higher mean BP levels and PIH in urban Ghana than in rural Ghana. BMI was independently related to high BP. Left unchecked, the increasing prevalence of overweight and obesity in Ghana will exacerbate PIH levels in Ghana.
PMCID: PMC3922859  PMID: 24228792
Blood pressure; Pregnancy induced hypertension; Pregnancy; Ghana
11.  Emergency Management of Hypertension in Children 
Systemic arterial hypertension in children has traditionally been thought to be secondary in origin. Increased incidence of risk factors like obesity, sedentary life-styles, and faulty dietary habits has led to increased prevalence of the primary arterial hypertension (PAH), particularly in adolescent age children. PAH has become a global epidemic worldwide imposing huge economic constraint on health care. Sudden acute increase in systolic and diastolic blood pressure can lead to hypertensive crisis. While it generally pertains to secondary hypertension, occurrence of hypertensive crisis in PAH is however rare in children. Hypertensive crisis has been further subclassified depending on presence or absence of end-organ damage into hypertensive emergency or urgency. Both hypertensive emergencies and urgencies are known to cause significant morbidity and mortality. Increasing awareness among the physicians, targeted at investigation of the pathophysiology of hypertension and its complications, better screening methods, generation, and implementation of novel treatment modalities will impact overall outcomes. In this paper, we discuss the etiology, pathogenesis, and management of hypertensive crisis in children. An extensive database search using keywords was done to obtain the information.
PMCID: PMC3345222  PMID: 22577545
12.  Clinical evaluation of the efficacy of Dashanga Kwatha Ghana Vati in the management of Urdhwaga Amlapitta (Non-ulcer dyspepsia) 
Ayu  2012;33(2):219-223.
A study has been designed to evaluate the effectiveness of Dashanga Kwatha Ghana Vati in Urdhwaga Amlapitta (non-ulcer Dyspepsia). Randomized single blind, placebo controlled study was conducted in 138 patients attending O.P.D. of department of Basic Principles, I.P.G.T. and R.A., Gujarat Ayurved University, Jamnagar, and grouped into two. Both the groups consumed two tablets of either Dashanga Kwatha Ghana Vati or placebo, twice daily after food for a period of eight weeks. The patients were followed upto four weeks, 110 patients had completed the treatment and no adverse effects were reported during the treatment. Both groups had improved in the clinical symptoms and overall statistical significance was observed in the differences of scores between the two groups.
PMCID: PMC3611627  PMID: 23559793
Dashanga Kwatha Ghana Vati; non-ulcer dyspepsia; Urdhwaga Amlapitta
13.  Preliminary study on the effect of a herbal formulation “Deepaniyavati” in hyperlipidemia 
To examine the effect of “DeepaniyaVati”, a herbal formulation in the management of hyperlipidemia, a randomized group pre-test post-test study trial was carried out on fifty male (30 to 70 yrs) hyperlipidemic volunteers who were asked to follow their normal routine diet and activity pattern throughout the investigation period. The formulation, prepared by mixing nine plant products in equal proportion, when given in a daily dose of 2g, twice a day for a period of one month, brought about an observable improvement in all the lipid parameters by significantly reducing total cholesterol (10%), low density lipoprotein cholesterol (12.76%), very low density lipoprotein cholesterol (27.4%), triglycerides (34.7%) and bringing these values much nearer to the normal levels. In control group, no such effect was noticed. A concomitant significant increase in the HDL-C levels suggests the possible utility of “Deepaniya Vati” in the management of hyperlipidemia and the need for further detailed study.
PMCID: PMC3453951  PMID: 23105260
Hyperlipidemia; herbal formulation; lipoproteins; cholesterol; triglycerides
14.  Clinical efficacy of Mehamudgara vati in type 2 diabetes mellitus 
Ayu  2011;32(1):30-39.
In type 2 diabetes, insulin resistance is the main problem that is associated with a cluster of conditions such as obesity and hyperlipidemia. The present study was designed with the objective to evaluate the role of Mehamudgara vati (MMV), which was expected to work at the level of Medodhatwagni due to its Medohara properties, to have an effective control on type 2 diabetes. To fulfill the objective, known patients of type 2 diabetes attending the OPD and IPD of Kayachikitsa Department, IPGT and RA, were selected and were divided in two groups. In Group A, MMV was given 3 tab. thrice a day with lukewarm water for 3 months and in Group B, the patients who were already taking modern antidiabetic treatment, although their blood sugar level was not well under control, were additionally given MMV in the same manner. The formulation has shown a highly significant decrease in the fasting and post-prandial blood sugar level. The formulation has also shown a synergistic action when combined with the modern antidiabetic drugs due to its known hypolipidemic, hypocholesterolemic, hepatoprotective, antihyperglycemic, antistress, antioxidant and immunomodulatory activities.
PMCID: PMC3215414  PMID: 22131755
Agni; antihyperglycemic; antihyperlipidemic; dosha; dushya; stress; type 2 diabetes
15.  Effect of Ayurvedic management in 130 patients of diabetic nephropathy 
Ayu  2011;32(1):55-58.
Diabetic nephropathy is a specific form of renal disease. It is a major cause of renal insufficiency and ultimately of death. The present study has been carried out to prove the efficacy of Ayurvedic drugs in the management of diabetic nephropathy, which can be helpful in reducing the need of dialysis and avoiding or delaying renal transplantation. A total of 130 patients of this disease were treated in IPD (Group A) and OPD (Group B). Ayurvedic formulations including Gokshuradi Guggulu, Bhumyamalaki, Vasa and Shilajatvadi Vati were given to all the patients for 2 months. Group A patients were given special planned food. Results were analyzed statistically using “t” test. In group A patients, highly significant reduction was found in the values of serum creatinine, blood urea and urinary excretion of albumin. Marked improvement was found in the patients’ general physical well-being, together with reduction in symptoms, in group A patients. This shows the importance of Pathyapathya in Ayurvedic management of the disease. This management may bring some new hope to the patients of diabetic nephropathy, which usually terminates to chronic renal failure and ultimately to death. Further studies are being carried out in this regard.
PMCID: PMC3215418  PMID: 22131758
Ayurveda; diabetic nephropathy; albuminuria
16.  Hypertension among older adults in low- and middle-income countries: prevalence, awareness and control 
Background This study uses data from the World Health Organization’s Study on Global Ageing and Adult Health (SAGE) to examine patterns of hypertension prevalence, awareness, treatment and control for people aged 50 years and over in China, Ghana, India, Mexico, the Russian Federation and South Africa.
Methods The SAGE sample comprises of 35 125 people aged 50 years and older, selected randomly. Hypertension was defined as ≥140 mmHg (systolic blood pressure) or ≥90 mmHg (diastolic blood pressure) or by currently taking antihypertensives. Control of hypertension was defined as blood pressure below 140/90 mmHg on treatment. A person was defined as aware if he/she was hypertensive and self-reported the condition.
Results Prevalence rates in all countries are broadly comparable to those of developed countries (52.9%; range 32.3% in India to 77.9% in South Africa). Hypertension was associated with overweight/obesity and was more common in women, those in the lowest wealth quintile and in heavy alcohol consumers. Awareness was found to be low for all countries, albeit with substantial national variations (48.3%; range 23.3% in Ghana to 72.1% in the Russian Federation). This was also the case for control (10.2%; range 4.1% in Ghana to 14.1% India) and treatment efficacy (26.3%; range 17.4% in the Russian Federation to 55.2% in India). Awareness was associated with increasing age, being female and being overweight or obese. Effective control of hypertension was more likely in older people, women and in the richest quintile. Obesity was associated with poorer control.
Conclusions The high rates of hypertension in low- and middle-income countries are striking. Levels of treatment and control are inadequate despite half those sampled being aware of their condition. Since cardiovascular disease is by far the largest cause of years of life lost in these settings, these findings emphasize the need for new approaches towards control of this major risk factor.
PMCID: PMC3937973  PMID: 24505082
Hypertension; older people; risk factors; developing countries
17.  Hypertensive Target Organ Damage in Ghanaian Civil Servants with Hypertension 
PLoS ONE  2009;4(8):e6672.
Low levels of detection, treatment and control of hypertension have repeatedly been reported from sub Saharan Africa, potentially increasing the likelihood of target organ damage.
A cross-sectional study was conducted on 1015 urban civil servants aged≥25 years from seven central government ministries in Accra, Ghana. Participants diagnosed to have hypertension were examined for target organ involvement. Hypertensive target organ damage was defined as the detection of any of the following: left ventricular hypertrophy diagnosed by electrocardiogram, reduction in glomerular filtration rate, the presence of hypertensive retinopathy or a history of a stroke.
Of the 219 hypertensive participants examined, 104 (47.5%) had evidence of target organ damage. The presence of target organ damage was associated with higher systolic and diastolic blood pressure levels. The odds of developing hypertensive target organ damage was five to six times higher in participants with blood pressure (BP)≥180/110 mmHg compared to those with BP<140/90 mmHg, and there was a trend to higher odds of target organ damage with increasing BP (p = 0.001). Women had about lower odds of developing target organ damage compared to men.
The high prevalence of target organ damage in this working population associated with increasing blood pressure, emphasises the need for hypertension control programs aimed at improving the detection of hypertension, and importantly addressing the issues inhibiting the effective treatment and control of people with hypertension in the population.
PMCID: PMC2729720  PMID: 19701488
18.  The Family Physician and Special Groups of Hypertensives 
Canadian Family Physician  1985;31:371-374.
Future hypertension research will include not only fundamental pathophysiology and new methods of drug therapy but also research into which groups require special treatment. Hypertension is most common in the elderly, but after age 70 is only weakly associated with cardiovascular morbidity and mortality, mainly in females, and more related to systolic hypertension than diastolic. Hypotensive therapy has not yet proven to be of benefit in this age group. Trials of therapy, perhaps especially in systolic hypertension, in women and in previous stroke victims could well be carried out cooperatively by family physicians. The effectiveness of salt reduction and weight reduction in lowering blood pressure is controversial, but could be tested in cooperative trials, especially for borderline hypertensives and possibly for children of hypertensive parents.
PMCID: PMC2327711  PMID: 21274111
Hypertension; age groups; research
19.  PA01.19. Clinical evaluation of pandughni vati & dhatri lauha vati on garbhini pandu (iron deficiency anaemia in pregnancy 
Ancient Science of Life  2012;32(Suppl 1):S69.
The desire to have a healthy progeny is innate & very intense in every living being. The hectic life and tremendous stress in today's world has made the conception & continuation of pregnancy to term very difficult. Anaemia is one of the common disease conditions which affect a pregnant woman. In Ayurvedic classics anaemia in pregnancy is taken under the Rasa Pradoshaja Vikara. It is also a Santharpanotha Vikara.
Total 26 patients were registered from O.P.D. And I.P.D. of the department of Streeroga & Prasootitantra, out of them 4 patients were discontinued. They were randomly divided in to two groups; Group A (n 12) Pandughni Vati 2 tablets of 250mg tds and Group B (n 10) Dhatri Lauha Vati 1 tablet of 250mg tds. Dhatri Lauha Vati was selected for the present study due to its Pandughna, Prinana, Raktaprasadana properties. AYUSH department has developed a compound formulation Pandughni Vati. As a part of its clinical trials the same drug was selected for present study.
Group A The result observed in Shwasa (dyspnoea) (60%) and Hridrava (palpitation) (53.33%) were highly significant statistically (<0.001). Daurbalya (33.33%), Shrama (fatigue) (40%), Aruchi (anorexia) (28.57%) and Pindikodvestana (55.55%) were decreased significant statistically (<0.05) whereas in Panduta (pallor) (24%) it was not significant. In Group B, results observed were highly significant statistically (<0.001) in Panduta (pallor) (50%) and Shwasa (dyspnoea) (56.25%). The results in Shrama (fatigue) (61.54%), Hridrava (palpitation) (55.55%), Aruchi (anorexia) (42.85%), Pindikodvestan, (49.49%) were significant
On comparing the effect of therapy study was finding better percentage improvement in-group B consistently in most of subjective and objective parameters. So it can be said that Dhatri Lauha Vati has somewhatbetter results, proving it better to Pandughni Vati.
PMCID: PMC3800949
20.  Safety and efficacy evaluation of Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) in dyslipidemia patients: A pilot prospective cohort clinical study 
Ayu  2012;33(2):197-201.
Cardiovascular disease has multifaceted in which dyslipidemia, inflammation, and immunity play an important role. Arjuna powder and Arogyavardhini Vati used for centuries has potential for combating these factors. Therefore, the objective of this study was to evaluate the safety and efficacy of Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) for dyslipidemia patients. Total of 108 patients were screened at CGHS Ayurvedic Hospital, New Delhi. Ninety-six patients satisfied inclusion criteria, and signed informed consent and detailed medical history was recorded. Arjuna powder (5 g, BD) for 3 weeks and then Arogyavardhini Vati (500 mg, BD) for 4 weeks were prescribed to the patients. The primary efficacy endpoint was reduction in serum total cholesterol, LDL, triglycerides, and increased HDL levels. Secondary endpoints included reduction in serum C-Reactive Protein (CRP) and blood glucose levels. Safety assessments included hepatic function (aminotransferase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), bilirubin, and β2 microglobulin), renal function (urea and creatinine and NGAL) tests, and urine mercury level. The study was completed by 87 patients. The male and female patients were 65.5% (57/87) and 34.5% (30/87), respectively. There was a significant reduction in total cholesterol, LDL, triglycerides, CRP, and blood glucose. However, raised HDL level was also observed. Safety assessment results showed no significant change in serum ALT, AST, ALP and bilirubin, urea, creatinine β2 microglobulin, and NGAL levels at the end of study as compared to the baseline levels. In conclusion, the results of the present prospective cohort study showed that Ayurvedic treatment (Arjuna powder and Arogyavardhini Vati) is safe and effective for dyslipidemia.
PMCID: PMC3611635  PMID: 23559790
Arjuna; Arogyavardhini Vati; dyslipidemia; efficacy; safety
21.  The Counseling Older Adults to Control Hypertension (COACH) Trial: design and methodology of a group-based lifestyle intervention for hypertensive minority older adults 
Contemporary clinical trials  2013;35(1):70-79.
The disproportionately high prevalence of hypertension and its associated mortality and morbidity in minority older adults is a major public health concern in the United States. Despite compelling evidence supporting the beneficial effects of therapeutic lifestyle changes on blood pressure reduction, these approaches remain largely untested among minority elders in community-based settings. The Counseling Older Adults to Control Hypertension trial is a two-arm randomized controlled trial of 250 African-American and Latino seniors, 60 years and older with uncontrolled hypertension, who attend senior centers. The goal of the trial is to evaluate the effect of a therapeutic lifestyle intervention delivered via group classes and individual motivational interviewing sessions versus health education, on blood pressure reduction. The primary outcome is change in systolic and diastolic blood pressure from baseline to 12 months. The secondary outcomes are blood pressure control at 12 months; changes in levels of physical activity; body weight; and number of daily servings of fruits and vegetables from baseline to 12 months. The intervention group will receive 12 weekly group classes followed by individual motivational interviewing sessions. The health education group will receive an individual counseling session on healthy lifestyle changes and standard hypertension education materials. Findings from this study will provide needed information on the effectiveness of lifestyle interventions delivered in senior centers. Such information is crucial in order to develop implementation strategies for translation of evidence-based lifestyle interventions to senior centers, where many minority elders spend their time, making the centers a salient point of dissemination.
PMCID: PMC3805359  PMID: 23462343
Hypertension; Minority Elders; Senior Centers; Therapeutic Lifestyle Changes
22.  OA01.10. Clinical study of klaibya (male sexual dysfunctions) with special reference to hypertension 
Ancient Science of Life  2012;32(Suppl 1):S10.
Klaibya (Male Sexual Dysfunction = MSD) is common among men of all ages, it has been recently estimated that more than 152 million men worldwide experienced sexual dysfunction in 1995, and that this number will rise by 170 million, to approximately 322 million by the year 2025. In the past years, it has been reported that most of the hypertensive patients having disability to perform sexual acts and comes under the MSD. To keep these facts in mind the present study aimed to evaluate the efficacy of the Gokshuradi Vati in the management of Klaibya with or without hypertension.
The patients identified and classified as suffering from klaibya with or without hypertension participated in the clinical trial in three groups. The trial drug Gokshuradi Vati (Su.) 2 tabs of 500 mg with anupana of GOKSURADI KWATHA 10 ml. was be administered to all the patients for 1 month. All the Patients were assessed on the basis of subjective and objective criteria.
The results showed statistically significant improvement in high blood pressure. Beside these, highly significant improvement was found in sperm count, serum testosterone level and IIEF-15 variables.
On the basis of the results this study concluded that hypertension and klaibya are having a strong relation in each other's pathogenesis. On the basis of our study, we can say that every patient of hypertension should be examined for Klaibya.
PMCID: PMC3800852
23.  Pre-hypertension in Uganda: a cross-sectional study 
Persons with a systolic blood pressure (BP) of 120 to < 140 or diastolic BP of 80 to < 90 mm hg are classified as having pre-hypertension. Pre-hypertension is associated with cardiovascular disease (CVD) risk factors, incident CVD and CVD mortality. Understanding determinants of pre-hypertension especially in low income countries is a pre-requisite for improved prevention and control.
Data were analyzed for 4142 persons aged 18 years and older with BP measured in a community cross sectional survey in Uganda. The prevalence of pre-hypertension was estimated and a number of risk factors e.g. smoking, use of alcohol, overweight, obesity, physical activity, sex, age, marital status, place of residence, and consumption of vegetables and fruits were compared among different groups (normotension, pre-hypertension, and hypertension) using bivariate and multivariable logistic regression.
The age standardized prevalence of normal blood pressure was 37.6%, pre-hypertension 33.9%, hypertension 28.5% and raised blood pressure 62%. There was no difference between the prevalence of hypertension among women compared to men (28.9% versus 27.9%). However, the prevalence of pre-hypertension was higher among men (41.6%) compared to women (29.4%). Compared to people with normal blood pressure, the risk of pre-hypertension was increased by being 40 years and above, smoking, consumption of alcohol, not being married, being male and being overweight or obese. Compared to pre-hypertension, hypertension was more likely if one was more than 40 years, had infrequent or no physical activity, resided in an urban area, and was obese or overweight.
More than one in three of adults in this population had pre-hypertension. Preventive and public health interventions that reduce the prevalence of raised blood pressure need to be implemented.
PMCID: PMC3833647  PMID: 24228945
Cardiovascular diseases; Non communicable diseases; Low income countries; Risk factors; Prevalence
24.  Prevalence, awareness and control of hypertension in estate workers in Malaysia 
Hypertension continues to be a major causative factor contributing to cardiovascular, cerebrovascular and renal morbidity and mortality.
The objective of this study was to assess the prevalence, awareness and control of hypertension in the estate population in Johor, Malaysia.
Patients and Methods:
A mercury sphygmomanometer was used to record systolic and diastolic blood pressures. Cross sectional population survey was carried out in the study.
The overall prevalence of hypertension in 903 subjects studied was 26.91% (243). A higher prevalence 27.65 % (133) was found in males against 26.07% (110) in females. Awareness of the disease was present in only 39% (96) of which 86.45% (83) received treatment. Among those who received treatment, control of hypertension was present in 15.66% (13).
The prevalence of hypertension among the estate population is lower than that of the general population of Malaysia, which can be attributed to their regular physical activity but the awareness, treatment, control and follow-up of patients is disappointingly low.
PMCID: PMC3271415  PMID: 22363074
Estate workers; hypertension; prevalence; physical activity
25.  Ghana's Burden of Chronic Non-Communicable Diseases: Future Directions in Research, Practice and Policy 
Ghana Medical Journal  2012;46(2 Suppl):1-3.
The prevalence of major chronic non-communicable diseases and their risk factors has increased over time and contributes significantly to the Ghana's disease burden. Conditions like hypertension, stroke and diabetes affect young and old, urban and rural, and wealthy and poor communities. The high cost of care drives the poor further into poverty. Lay awareness and knowledge are limited, health systems (biomedical, ethnomedical and complementary) are weak, and there are no chronic disease policies. These factors contribute to increasing risk, morbidity and mortality. As a result chronic diseases constitute a public health and a developmental problem that should be of urgent concern not only for the Ministry of Health, but also for the Government of Ghana. New directions in research, practice and policy are urgently needed. They should be supported by active partnerships between researchers, policymakers, industry, patient groups, civil society, government and development partners.
PMCID: PMC3645141  PMID: 23661810
chronic non-communicable diseases; health systems; policy; research; Ghana

Results 1-25 (574406)